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Expressed protein ligation to probe regiospecificity of
heterocyclization in the peptide antibiotic microcin B17
Ranabir Sinha Roy*†, Owen Allen† and Christopher T Walsh
Background: The Escherichia coli peptide antibiotic microcin B17 (MccB17)
contains thiazole and oxazole heterocycles derived from a distributive yet
directional cyclization of cysteines and serines in the McbA precursor catalyzed
by MccB17 synthetase. Whether the formation of upstream rings potentiates
downstream heterocyclization has not been previously determined.
Results: McbA fragments (46–61 residues) containing glycine substitutions
or homocysteine at select upstream cysteine or serine sites were assembled
using expressed protein ligation (EPL). Most of these substrates were only
partially cyclized by MccB17 synthetase, in contrast to the efficient
processing of wild-type McbA1–61. Homocysteine was not processed to the
six-membered heterocycle.
Conclusions: The formation of upstream rings in McbA potentiates the
cyclization of carboxy-terminal cysteines and serines, probably by selecting
against unfavorable substrate conformations. EPL allows structure–function
analysis including unnatural amino acid placements to probe the
regiospecificity and chemoselectivity of post-translational heterocyclization
during antibiotic maturation.
Introduction
Several natural products contain oxazole and thiazole hete-
rocycles derived from precursor peptides containing
Xaa–Ser/Cys sequences (where Xaa represents any amino
acid) [1]. These molecules often exhibit useful therapeutic
properties, ranging from the anticancer activity of the bithi-
azole-containing drug bleomycin A [2], to the gram-positive
antibiotic activity of thiostrepton [3], which is assembled
around a pyridine-trithiazole scaffold. Microcin B17
(MccB17), a DNA gyrase inhibitor secreted by certain
strains of Escherichia coli [4,5], belongs to this family and
contains two oxazoles, two thiazoles, a 4,2-linked oxazole–
thiazole, and the analogous 4,2-thiazole–oxazole, all within
a stretch of 43 residues. The cloning of the genes for
MccB17 production (mcbABCD) [6], export (mcbEF) and
immunity (mcbG) [7], and subsequent purification of the
heterocyclization catalyst (the multimeric MccB17 syn-
thetase enzyme complex composed of the McbB,C,D gene
products) [8], have made the biosynthesis of this peptide
antibiotic a convenient system for investigating the mecha-
nism and specificity of post-translational heterocyclization
of serine and cysteine residues to oxazoles and thiazoles.
Certain structural elements of the MccB17 precursor
polypeptide (the 69 amino acid McbA gene product;
Figure 1) are important for substrate recognition and
heterocyclization by the synthetase. In particular, a cis-
acting amino-terminal 26-residue helical propeptide
sequence is critical for synthetase recognition [8,9], and an
adjacent 13-residue polyglycine linker sets the register for
downstream Gly–Ser, Gly–Cys, Gly–Ser–Cys and Gly–
Cys–Ser sequences that are cyclized to the eight hetero-
cycles in mature MccB17 (numbered consecutively from
the amino terminus in Figure 1) [10]. The detection of par-
tially processed McbA intermediates containing 1–7 rings
using mass spectrometry (N.L. Kelleher, C. Hendrickson
and C.T.W., unpublished observations), together with the
purification of partially cyclized MccB17 isoforms from
extracts of microcin-producing E. coli cells [11], reveals
that oxazole and thiazole formation occurs distributively
rather than processively, with partially cyclized intermedi-
ates being released from the enzyme complex. Tandem
mass spectrometry (MS/MS) analysis of these intermedi-
ates (N.L. Kelleher, C. Hendrickson and C.T.W., unpub-
lished observations) has shown that the overall
heterocyclization of McbA is remarkably directional
(amino → carboxyl terminus), given that the modified cys-
teines and serines are remote in primary sequence from
the avidly recognized propeptide helix and are located
within a glycine-rich domain (McbA39–65) that does not
contribute significantly to the binding affinity of the sub-
strate [9]. These observations indicate that the processing
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of McbA may be influenced by subtle effects that extend
beyond the propeptide–synthetase interaction.
To determine whether heterocycle formation influences
the directional processing of McbA, we have replaced
select upstream Ser/Cys cyclization sites with glycine
residues. Whether or not these ‘knockout’ mutations
(corresponding to rings 1–4) affect the heterocyclization
of downstream cysteines and serines has been investi-
gated in a set of McbA fragments encompassing one or
more heterocyclization sites (rings 2–6). To date, such
studies have been precluded by difficulties in the assem-
bly of the requisite mutant McbA sequences. Site-
directed mutagenesis efforts have been hampered by
codon degeneracy and mispriming in the polyglycine
coding regions of mcbA, and the solid-phase synthesis of
such McbA analogs suffers from low yields because of the
high glycine content (up to 48%), which results in poor
coupling efficiencies.
Recently, the method of expressed protein ligation (EPL)
has been described as a strategy that exploits the machin-
ery of protein splicing [12] to ligate synthetic peptides to
the carboxyl termini of recombinant proteins [13]. We
have now utilized this technique to generate the McbA
knockout mutants as contiguous sequences derived from
synthetic peptides (6–21 residues) that are ligated to the
first 40 residues of a mutant McbA protein (containing a
Ser40→Gly mutation), which is tagged by maltose-
binding protein (MBP). The MBP-tagged McbA1–40(S40G)
serves as the substrate-recognition determinant for intein
catalysis (Figure 2). The heterocyclization of these
mutant McbA domains (46–61 residues) within the
ligated MMP (MBP–McbA1–40(S40G)–peptide) chimeras,
when compared with that of His6-tagged McbA1–61,
reveals the importance of upstream rings for the efficient
processing of McbA and the biosynthesis of the eight-ring
MccB17 antibiotic.
Results
Development of an EPL strategy for the McbA knockout
mutants
A tetramodular MBP–McbA1–40(S40G)–intein–CBD (MMIC;
CBD is a chitin-binding domain) fusion protein containing
the MccB17 substrate-recognition domain, an intein
domain for protein splicing, and suitable affinity tags for
rapid purification was designed to enable assembly of
knockout mutants using EPL. The expression vector for
recombinant MMIC protein was constructed by fusing
sequentially and in frame the genes encoding MBP, a
linker containing a thrombin restriction site (LVPRGS,
using single-letter amino acid code), and the McbA1–40(S40G)
mutant fragment, to the coding sequence of the Saccha-
romyces cerevisiae VMA1 intein [14] fused to a CBD in the
commercially available pTYB1 vector (New England
Biolabs, MA). The MBP tag provides a useful epitope at
the amino terminus of the McbA1–40(S40G) substrate-recog-
nition determinant for immunoblot analysis of the ligation
products, does not interfere with heterocyclization by
MccB17 synthetase [10], and can be removed by a throm-
bin digest prior to mass spectrometric analysis of the hete-
rocyclization products. The Ser40→Gly mutation in
McbA1–40 introduces a Gly40–Cys41 splice junction
between the McbA1–40 and intein domains (using the num-
bering scheme of McbA), which favors the formation of a
Cys41 α-thioester during intein-mediated splicing. This
mutation also corresponds to deletion of the amino-termi-
nal oxazole in processed McbA (ring 1), which allowed the
importance of this heterocycle in the cyclization of down-
stream sites to be determined. The dual-tagged MMIC
protein was expressed under the control of the T7 pro-
moter in E. coli BL21(DE3) cells, and immobilized on an
affinity column prior to the ligation reactions. Although
MMIC can be purified using either MBP-directed
(amylose) or CBD-directed (chitin) column strategies, the
latter gave consistently higher yields of ligated product,
and was adopted as the default method for protein purifica-
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Figure 1
Sequence of (a) the McbA precursor and
(b) the mature MccB17 antibiotic. The McbA
fragments described in this study are
delineated by residue number (dotted lines).
The propeptide and linker regions in McbA
are also labeled. The four oxazoles (red) and
four thiazoles (blue) in mature MccB17 are
numbered consecutively from the
amino terminus.
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(a)  McbA
(b)  MccB17
tion and immobilization. The crude protein extract was
loaded on a chitin column, which was washed extensively
with column buffer. The chitin beads were then incubated
in 30 mM dithiothreitol (DTT) to promote formation of
the Cys41-DTT α-thioester (MM–Cys41–DTT;
Figure 2), immediately prior to the actual transthioesterifi-
cation/ligation reaction with target peptides P1–P7.
MM–Cys41-DTT is a viable substrate for EPL
The first target peptide to be tested for EPL-mediated
splicing with the MMIC protein and subsequent hetero-
cyclization by MccB17 synthetase was the hexapeptide P1
(NH2-CGGQGG-CONH2, Table 1), which corresponds to
the McbA41–46 fragment. The amino-terminal cysteine
residue of this target sequence, essential for the ligation
methodology (Figure 2), is also the sole residue that can
be subsequently cyclized (ring 2 of MccB17). Incubation
of the 103.9 kDa MMIC protein (~40 nmoles, immobi-
lized on chitin beads and activated with DTT), with 2 ml
of a 2 mM solution of peptide P1 (100-fold molar excess)
for 48 hours led to the elution of a lower molecular weight
species (lane E, Figure 3), which migrated in sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) with a mass corresponding to that of the antici-
pated MBP–McbA1–40–P1 chimera (MMP1; 46.9 kDa). To
confirm its identity, this ligated product was subjected to
immunoblot analysis, using either anti-MBP or anti-intein
antibodies as probes. The MMP1 chimera was recognized
only by anti-MBP antibodies, which target the amino-ter-
minal MBP domain (lane W, Figure 3). The absence of a
corresponding immunoblot signal with anti-intein anti-
bodies (data not shown) confirmed the intein→P1 frag-
ment swap that released the MMP1 chimera from the
57.5 kDa intein–CBD portion of MMIC (‘IC’; Figure 2),
and permitted its selective elution from the chitin beads.
Residual full-length MMIC protein and the IC fragment
(which was significantly degraded by proteolysis) were
subsequently stripped from the chitin beads by an SDS
wash and their identities confirmed by similar
immunoblot analysis (data not shown). Typically,
5–15 nmoles of purified EPL chimera were obtained after
buffer exchange and concentration of the eluate.
The MMP1 chimera represents an amino-terminal MBP
fusion of the contiguous McbA1–46(S40G) fragment, which
contains a single Gly39–Gly40–Cys41 sequence that is the
precursor to a monothiazole. An authentic sample of this
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Figure 2
Construction of McbA knockout mutants using expressed protein ligation
(EPL). The tetramodular MMIC (MBP–McbA1–40(S40G)–intein–chitin-
binding domain) protein is initially immobilized on a chitin column and
incubated with dithiothreitol (DTT) and synthetic peptides P1–P7. The
intein-catalyzed splicing reaction involves the intermediacy of an
α-thioester (MM–Cys41–DTT, using the numbering scheme of McbA),
which is captured via transthioesterification by an amino-terminal cysteine
(or homocysteine) residue in the target peptide. The ligated sequences in
chimeras MMP1–MMP7 encompass 46, 50, 54 or 61 residues of McbA,
and selectively elute from the column. The intein–CBD (IC) fragment and
unreacted MMIC substrate are retained on the chitin beads.
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Table 1
Primary sequence of synthetic peptides used for EPL in this
study. 
The sequence of McbA41–69 is shown for comparison. Cysteine and
serine residues that are cyclized to thiazoles and oxazoles in native
MccB17 are highlighted in orange, as are potentially cyclizable
residues in peptides P1–P7. Two serine residues (underlined) remain
unprocessed in the mature antibiotic. Residue substitutions compared
with the wild-type sequence are highlighted in red. X, homocysteine.
McbA41–69 C G G Q G G G C G G C S N G C S G G N G G S G G S G S H I
    P1 C G G Q G G
    P2 C G G Q G G G C G G
    P3 C G G Q G G G G G G C S G G
    P4 C G G Q G G G G G G G G N G C S G G N G G
    P5 C G G Q G G G G G G G G N G C C G G N G G
    P6 X G G Q G G
    P7 X G G Q G G G C G G
Peptide
            
Sequence
41                     46             50             54                           61  69
fusion protein (MBP–McbA1–46(S40G), ‘GGC’) constructed
using conventional cloning techniques has previously
been reported [15]. Formation of the monothiazole in
both samples by affinity-purified MccB17 synthetase [10]
was monitored using an immunoblot assay with heterocy-
cle-recognizing (anti-MccB17) antibodies [16]. As antici-
pated, time-dependent heterocycle formation was
observed with the MMP1 chimera (Figure 4), confirming
the ability to generate competent heterocyclization sub-
strates using EPL.
Heterocyclization efficiency of chimeras MMP2–MMP5
lacking select upstream Cys/Ser sites
For the next set of substrates, McbA fragments up to 21
residues in length were synthesized (Table 1, peptides
P2–P5). These sequences incorporate cyclizable cysteine
and serine residues at various loci (precursors to rings 2–6),
with glycine substitutions at specific sites (rings 3 and/or 4).
Each peptide was ligated to the McbA1–40(S40G) domain in
MMIC to generate McbA sequences corresponding to 50,
54 or 61 residues, with a common cyclization site
(Gly40–Cys41) being retained at the splice junction.
Chimera MMP2 introduces a second cysteine (Cys48,
ring 3), whereas MMP3 has a Gly48 knockout at this posi-
tion with a Gly50–Cys51–Ser52–Gly53 site further down-
stream (a variant of the Gly50–Cys51–Ser52–Asn53
precursor sequence for ring 4). The P4 and P5 pair of 21-
mers each create a ligated McbA1–61 with glycine residues in
place of Ser40 (ring 1), Cys48 (ring 3), Cys51 (ring 4) and
Ser52 (which remains uncyclized in mature MccB17).
Chimera MMP4 contains the Gly54–Cys55–Ser56 sequence
that forms a 4,2-linked oxazole–thiazole in MccB17 (rings 5
and 6), whereas MMP5 contains a non-native 4,2-bithiazole
precursor sequence (Gly54–Cys55–Cys56) at this site.
As with the MMP1 substrate, a time-dependent increase
in immunoblot signal with anti-MccB17 antibodies corre-
sponding to the formation of heterocyclic products was
observed for each chimera MMP1–MMP5 (data not
shown), consistent with the cyclization of at least one cys-
teine and/or serine residue within the corresponding
target sequences. To determine whether Cys/Ser residues
downstream of the Cys41 (monothiazole) junction were
being converted to heterocycles, the products were further
analyzed by matrix-assisted laser desorption ionization
mass spectrometry (MALDI–TOF MS) after cleavage of
the MBP tag with thrombin, which leaves a Gly–Ser
dipeptide moiety appended to the amino terminus. This
MS analysis allowed the heterocycle content of each
cyclized McbA fragment to be determined explicitly
(20 Da decrease in mass per heterocycle formed, corre-
sponding to the loss of water and two hydrogen atoms).
The MALDI–TOF mass spectrum of the Gly–Ser–
McbA1–50 mutant sequence from thrombin-digested
MMP2 (two potential thiazoles from Cys41 and Cys48),
after incubation with synthetase for 24 hours, is illustrated
in Figure 5b. Molecular ions corresponding to a 1:1
mixture of monothiazole (M-20) and bithiazole (M-40)
species were observed. A similar analysis of processed
MMP1 confirmed that Cys41 was quantitatively cyclized
to the monothiazole (data not shown). In a separate study,
tandem MS of partially processed McbA substrates has
revealed that Cys41 is cyclized to the thiazole prior to
Cys48 (N.L. Kelleher, C. Hendrickson and C.T.W.,
unpublished observations). Taken together, these data
suggest that it is the downstream Cys48 residue that fails
to get completely modified in the MMP2 chimera. The
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Figure 3
SDS–PAGE and immunoblot analysis of EPL with the MMIC substrate
and peptide P1. The ligated MBP–McbA1–40(S40G)–P1 (MMP1) chimera
elutes from the chitin column with the anticipated mass (46.9 kDa,
lane E). The amino-terminal MBP tag in this protein is recognized by
anti-MBP antibodies in the western analysis of the eluate (lane W),
which also reveals traces of full-length MMIC protein (103.9 kDa). The
faint (< 10%) band at ~46 kDa in each lane is consistent with unligated
MBP–McbA1–40(S40G) protein (46.4 kDa) resulting from background
hydrolysis of the MM–Cys41-DTT thioester intermediate.
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Figure 4
Immunoblot assay for heterocyclization of MBP–McbA1–46(S40G).
Samples of this McbA analog prepared by site-directed mutagenesis
(MBP–McbA1–46(S40G), ‘GGC’) or EPL (MMP1) were incubated with
MccB17 synthetase and analyzed for heterocycle formation using a
western blot assay and anti-MccB17 antibodies as described in the
text. A time-dependent immunoblot signal corresponding to formation
of the monothiazole species was observed in both cases. Authentic
MBP–McbA1–46(S40G) monothiazole was used as a standard (S).
S 0 5 10 15 20 30 60 120 180 S min
GGC
MMP1
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yield of bithiazole product did improve slightly (59%)
upon doubling the incubation time with enzyme, so sub-
sequent substrates were incubated with the synthetase for
48 hours prior to MS analysis.
The McbA1–54 sequence in chimera MMP3 contains
three potentially cyclizable residues (Cys41, Cys51–
Ser52), which should afford one thiazole and a 4,2-linked
thiazole–oxazole. Ser52 remains uncyclized during the
biosynthesis of MccB17 from native McbA, however [4].
This regiospecificity may be controlled in part by Asn53,
because polar residues (e.g. asparagine or histidine)
disrupt heterocyclization when inserted immediately
downstream of the Gly39–Ser40–Cys41 bisheterocycliza-
tion site in McbA1–46 [10]. In an attempt to cyclize Ser52
in the MMP3 chimera, Asn53 was substituted by glycine
because this residue flanks each site that is completely
processed in McbA. MS analysis of MMP3 after a 48 hour
incubation with MccB17 synthetase revealed conversion
only to a double-ring (M-40) species (Figure 5d),
however. This partially processed product was treated
with iodoacetamide in a thiol-directed alkylation strategy
to determine whether any of the cysteine residues
remained uncyclized. As a positive control, the mixture of
heterocyclic MMP2 products previously analyzed by MS
was also treated with iodoacetamide to confirm alkylation
of the unprocessed cysteine residue in the corresponding
monothiazole species. As illustrated in Figure 5a, the
resulting mass spectrum revealed a shift in the M-20 mol-
ecular ion (by +57 Da), corresponding to acetamidylation
of the free cysteine in the monothiazole MMP2 interme-
diate. The fully cyclized bithiazole M-40 product
remained unchanged in mass, consistent with the
absence of free thiols in this polypeptide. Similarly, the
M-40 molecular ion in the mass spectrum of processed
MMP3 did not show an increase in mass upon treatment
with the alkylating reagent (Figure 5c). These data
strongly suggest that it is the serine residue in the Gly50–
Cys51–Ser52 site of MMP3 that fails to get modified to
the oxazole.
Chimeras MMP4 and MMP5 also contain three cycliz-
able residues each, including a bisheterocyclic site that is
further downstream in primary sequence compared with
that in substrate MMP3. The mass spectrum of processed
MMP4 (two potential thiazoles from Cys41 and Cys55
and one potential oxazole from Ser56) showed complete
conversion only to a monoheterocyclic (M-20) species
(Figure 6b). A similar result was obtained with MMP5
(three potential thiazoles from Cys41, Cys55 and Cys56),
although traces of the bithiazole (M-40) and trithiazole
(M-60) species were also detected (~15% each;
Figure 6a). Iodoacetamide alkylation of processed MMP4
resulted in a shift of the (M-20) molecular ion by +57 Da
(data not shown), suggesting that one of the two cys-
teines and the serine residue in this species were not
cyclized by the synthetase. Because Cys41 in the splice
junction of chimeras MMP1–MMP3 is efficiently
processed to the thiazole, and tandem MS has revealed
that this residue is precursor to the first heterocycle
formed in McbA (N.L. Kelleher, C. Hendrickson and
C.T.W., unpublished observations), these data indicate
that the downstream Gly54–Cys55–Ser56 site in MMP4
is not detectably modified by the synthetase, and that the
corresponding Gly54–Cys55–Cys56 sequence in MMP5
is only inefficiently processed to the monoheterocyclic
and bisheterocyclic moieties.
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Figure 5
MALDI–TOF MS analysis of heterocyclization in chimeras (a,b) MMP2
and (c,d) MMP3. Mass spectrum of processed MMP2 (b) reveals a 1:1
mixture of monothiazole (M-20; Mcalc = 4526.2 Da, Mobs = 4526.2 Da)
and bithiazole (M-40; Mcalc = 4506.2 Da, Mobs = 4507.1 Da) species.
Treatment with iodoacetamide (a) causes a shift of the monothiazole
molecular ion by + 57 Da (Mcalc = 4583.2 Da, Mobs = 4583.3 Da),
corresponding to alkylation of a single cysteine. Mass spectrum of
processed MMP3 (d) reveals complete conversion to a bisheterocyclic
(M-40; Mcalc = 4764.3 Da, Mobs = 4764.8 Da) species, which is
unchanged upon treatment with iodoacetamide (c). Unassigned peaks
corresponding to fragments or trace impurities are indicated with an
‘X’. These data indicate that although both cysteines in MMP3 are
cyclized to thiazoles, the single serine (Ser52) in this substrate remains
unprocessed. IA, iodoacetamide.
4700 4720 4740 4760 4780 4800 4820 4840
4480 4500 4520 4540 4560 4580 4600 4620
Mass (Da)
Mass (Da)
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X
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Synthetase-mediated processing of His6–McbA1–61
containing intact upstream heterocyclization sites
The His6-tagged McbA1–61 fragment encompasses all four
cysteines and two of the four cyclizable serines in full-
length McbA, which are located at four distinct sites and
are precursors to rings 1–6 of the mature antibiotic. This
substrate contains intact upstream sites (corresponding to
rings 1–3), some of which were substituted with glycine
residues in substrates MMP1–MMP5. In contrast to the
incomplete cyclization of most of the chimeric substrates,
incubation of His6–McbA1–61 with MccB17 synthetase for
48 hours afforded completely processed (six-ring)
polypeptide as the major product (Figure 7). Partially
cyclized intermediates (1–5 rings) were also observed, as
anticipated for a distributive process. Given that the
overall heterocyclization of substrate is directional
(amino → carboxyl terminus), these data underline the
importance of rings 1–3 for the efficient cyclization of
downstream Cys/Ser residues.
Homocysteine as a substitute for cysteine in ligating
peptides
The EPL strategy used with amino-terminal cysteine
peptides P1–P5 introduces a Gly40–Cys41 splice junc-
tion linking McbA1–40(S40G) to each target peptide in
chimeras MMP1–MMP5. We have investigated whether
an alternate thiol residue can replace this cysteine to
produce a ‘silent’ splice junction that is not subsequently
cyclizable by MccB17 synthetase. The nonstandard
residue homocysteine (HCys) was incorporated at the
amino termini of target peptides P6 and P7, which are
otherwise identical to peptides P1 and P2, respectively
(Table 1). The corresponding substrate chimeras MMP6
and MMP7 were readily generated by EPL, although
incubation of the peptides with MMIC and DTT was
extended to 72 hours, because capture of the
MMIC–Cys41-DTT α-thioester by homocysteine is a
slower process involving the formation of a six-mem-
bered cyclic intermediate. MALDI–TOF MS analysis
following thrombin digest of the MBP tags and high per-
formance liquid chromatography (HPLC) purification
indicated the correct molecular weight for each McbA
analog (data not shown). Because such data cannot
confirm rearrangement of the thioester linkages to the
amide forms at each homocysteine splice junction [17],
each McbA analog was also treated with iodoacetamide to
determine the free thiol content. MALDI–TOF analysis
revealed quantitative acetamidylation of HCys41 in
MMP6 (Mcalc = 4343.1 Da; Mobs = 4343.0 Da), and of
both HCys41 and Cys48 in MMP7 (Mcalc = 4674.2 Da;
Mobs = 4674.9 Da), confirming that the desired S→N acyl
shift had occurred after thiol capture by homocysteine in
peptides P6 and P7.
Chimera MMP6 incorporates a Gly40–HCys41 splice
junction with no cyclizable cysteines or serines in the
ligated sequence. The absence of an immunoblot signal
upon incubation of MMP6 with MccB17 synthetase (data
not shown) suggested that either the HCys residue was
not cyclized to a six-membered heterocycle or the anti-
MccB17 antibodies were unable to recognize this modi-
fied epitope. MS analysis subsequently revealed that the
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Figure 6
MALDI–TOF MS analysis of heterocyclization in chimeras (a) MMP5
and (b) MMP4. Incubation of MMP4 with MccB17 synthetase for 48 h
resulted in incomplete cyclization to a monoheterocyclic (M-20)
species (Mcalc = 5297.5 Da, Mobs = 5299.8 Da). For MMP5, traces
(~15%) of bithiazole (M-40) species (Mcalc = 5296.8 Da,
Mobs = 5300.0 Da) and trithiazole (M-60) product (Mcalc = 5276.8 Da,
Mobs = 5278.2 Da) were observed in addition to the monothiazole
(M-20) species (Mcalc = 5316.8 Da, Mobs = 5316.4 Da). Molecular ions
marked with a star correspond to neutral loss peaks (loss of ammonia).
5200 5240 5280 5320 5360 5400
Mass (Da)
M-20
M-20
M-40
M-60
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(a)
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Figure 7
MALDI–TOF mass spectrum of processed His6–McbA1–61. Although
the amino-terminal His6 tag incorporates a thrombin restriction site
(LVPRGSH), it was retained for the MS analysis. Molecular ions
corresponding to species containing 0–6 rings were detected as
neutral loss peaks (loss of ammonia). The ring content is listed above
each molecular ion. Additional neutral loss peaks (loss of one or two
water molecules from the six-ringed species) are also indicated.
7000 7100 7200 7300 7400 7500
Mass (Da)
6
5
4 3
2 1
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6 –H 2O
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His6 –McbA1–61: GSSHHHHHHSSGLVPRGSH–McbA1–61
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MMP6 chimera was indeed not modified by the syn-
thetase, because a single molecular ion corresponding to
uncyclized material was observed (Mcalc = 4286.12 Da,
Mobs = 4286.21 Da). Chimera MMP7, in contrast, contains
an additional Cys48 site downstream of the splice junc-
tion, and monothiazole formation in this chimera was con-
firmed by immunoblot assay (Figure 8). The formation of
a single thiazole in MMP7 (from Cys48) compared with
two thiazoles in the MMP2 chimera (from Cys41 and
Cys48) is predicted to result in a 50% decrease in
immunoblot signal intensity with the former, provided the
cyclization efficiency remains unchanged. The processing
of Cys48 (~59% complete in MMP2) was further reduced
in MMP7, however, as revealed by an ~70% decrease in
normalized immunoblot signal for the latter (Figure 8).
With the proviso that HCys41 does not significantly inter-
fere with the cyclization of downstream Cys/Ser residues,
these results identify the thiazole formed from Cys41 in
McbA (ring 2) as also being important for increasing the
efficiency of downstream heterocyclization.
Discussion
The E. coli peptide antibiotic MccB17 undergoes two dis-
tinct post-translational modification events to attain
antibacterial activity from its 69 amino acid precursor,
McbA. The initial cyclodehydration of 14 of the 69
residues at six distinct sites is followed by proteolysis of
the first 26 amino acids to produce the 43-residue mature
antibiotic containing four oxazoles and four thiazoles
[5,16]. Recently, we have detected a ninth heterocycle
involving a 4,2-bisheterocycle moiety from Gly50–Cys51–
Ser52 in an overproducing strain [11]. It is likely that these
tandem heterocycles are DNA intercalating moieties, and
initial structure–activity relationship (SAR) studies show
that alterations at the Cys55–Ser56 site are more deleteri-
ous than those at Ser40–Cys41 for loss of antibiotic activity
against sensitive strains of E. coli [11].
We have proposed that the heterocyclization of McbA
commences when the McbD subunit of the McbB,C,D
synthetase complex binds to the amino-terminal propep-
tide helix of the McbA substrate (McbA1–26) [18]. Most of
the substrate-binding affinity appears to be derived from
this interaction, because the 26 amino acid propeptide
fragment alone is a potent competitive inhibitor of the
synthetase, with a Ki (2 µM) comparable to the KM of sub-
strate (2.3 µM) [8]. The McbB subunit is proposed to
function as a zinc-dependent cyclodehydratase that con-
verts cysteine and serine residues in McbA (downstream
of the McbA27–39 polyglycine spacer) to the corresponding
oxazole and thiazole heterocycles. The desaturation of
these 4,5-dihydro intermediates to oxazoles and thiazoles
is presumably catalyzed by McbC, a putative dehydroge-
nase that contains flavin. Substrate-dependent ATP
hydrolysis (most probably by McbD [19]) is critical for the
heterocyclization process, and is proposed to provide a
conformational switch that either activates the synthetase
complex, or serves a motor function in the distributive
heterocyclization of all eight Cys/Ser residues.
Although the model for substrate processing by MccB17
synthetase reconciles the proposed chemistry of heterocy-
clization with the issue of subunit function in the multi-
meric enzyme complex [18], it does not provide insight
into the directional, yet distributive mode of hetero-
cyclization that is observed both in vitro [10,11] and in vivo
[11]. Specifically, it does not explain how the synthetase
manages to release partially cyclized intermediates
without disrupting the order (amino → carboxyl terminus)
in which the six heterocyclization sites (dispersed over 30
residues in McbA) are processed. Because the glycine-rich
domain in which these residues are located (McbA39–65)
presumably adopts a random-coil conformation, and com-
petition assays have revealed that the unprocessed
McbA27–69 fragment alone is not detectably bound by the
synthetase [8,9], a possible explanation for the observed
directionality is that the formation of rings proximal to the
tightly bound amino-terminal propeptide helix results in
conformational or structural perturbations that potentiate
the cyclization of remaining sites further downstream in
the substrate. To determine the validity of this hypothe-
sis, we have altered the carboxy-terminal third of McbA,
focusing on the McbA40–61 sequence, which contains six of
the eight cyclizable residues (lacking oxazoles 7 and 8).
Two features of the McbA substrate and its recognition
by MccB17 synthetase make extensive SAR studies of
carboxy-terminal segments problematic. First, the amino-
terminal 39 residues must be connected in cis [8,9] and
second, the run of glycines between residues 30 and 39
renders mutagenesis or chemical synthesis strategies
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Figure 8
Immunoblot analysis of processed chimeras MMP2 and MMP7. The
Gly40–Cys41 splice junction in MMP2 is replaced by a ‘silent’
Gly40–HCys41 sequence in MMP7, which does not interfere with
downstream heterocyclization. The incomplete formation of thiazole 3
from Cys48 is caused by the absence of oxazole 1 in chimera MMP2
(~59% yield by MS) is more pronounced in MMP7, which lacks both
oxazole 1 and thiazole 2 (~48% yield after normalization for
heterocycle content).
0   5   10 15 20 30 60 120 180 min
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error-prone when exploring variations in Cys/Ser sites
between positions 40 and 65. We turned, therefore, to the
recently described EPL methodology of Muir et al. [13],
using the tetramodular MMIC protein as substrate and
catalyst. Muir et al. [13] utilized thiophenol to facilitate
EPL catalysis; we have used DTT instead, such that the
substrate for thiol capture by nucleophilic peptides P1–P7
is the nascent MM–Cys41-DTT α-thioester intermediate
generated by intein catalysis. An S→N acyl shift subse-
quently completes the peptide ligation. The EPL strat-
egy is robust, and in its present form can be generalized
for constructing McbA analogs with any sequence varia-
tion in residues 42–69 to probe determinants of substrate
heterocyclization or antibiotic activity. Purification of the
ligated MMP products is straightforward and the EPL
protocols have been optimized to minimize any compet-
ing hydrolysis of MM–Cys41-DTT before capture by the
synthetic peptides, which would yield contaminating
MBP–McbA1–40(S40G) protein (a competitive inhibitor of
MccB17 synthetase).
The processing of EPL chimeras MMP1–MMP7 by affin-
ity-purified MccB17 synthetase was compared with that of
His6-tagged McbA1–61, which contains intact sites for rings
1–6. The heterocyclization of each substrate was measured
qualitatively using immunoblot assays (with thiazole- and
oxazole-recognizing anti-MccB17 antibodies) and quantita-
tively using MALDI–TOF MS (20 Da decrease in mass
per heterocycle formed). A typical distributive pattern of
heterocyclization was observed for His6–McbA1–61, with
detection of the entire spectrum of species containing
1–6 rings. In contrast, most of the chimeric substrates were
only partially processed by the synthetase. Treatment of
these species with iodoacetamide to alkylate any unmodi-
fied cysteines and MS analysis of the products (57 Da mass
increase per uncyclized cysteine) allowed the number of
thiazoles (and hence the net heterocycle content) to be
unambiguously determined.
The Ser40→Gly mutation in MMIC deletes the amino-
terminal oxazole (ring 1 of MccB17) in each EPL chimera.
The absence of this heterocycle did not affect the cycliza-
tion of Cys41 in MMP1, although the Cys48 site further
downstream in chimera MMP2 remained only partially
modified, even after a 48 hour incubation with synthetase.
Such incomplete cyclization of downstream residues was
context dependent, because Cys51 (ring 4) was efficiently
processed in MMP3, even though two upstream heterocy-
cles (rings 1 and 3) were absent. This differential process-
ing of downstream sites suggests that the cyclization of
specific sites in McbA may be potentiated by conforma-
tional changes induced by the upstream heterocycles,
which increase the delivery of these residues to the syn-
thetase active site. An alternate hypothesis involving spe-
cific recognition of upstream heterocycles by MccB17
synthetase to progressively increase the binding affinity of
intermediates appears unlikely, because neither the eight-
ring MccB17 antibiotic (50 µM) nor the unprocessed
McbA27–69 fragment (250 µM) inhibited the processing of
MBP-tagged McbA (2 µM, data not shown).
As illustrated in Figure 9, formation of the 4,2-linked
oxazole–thiazole (rings 1 and 2) in native McbA can
induce a chain reversal in the McbA polypeptide of up to
180° (resembling a β turn), which may facilitate the deliv-
ery of Cys48 to the synthetase. Deletion of ring 1 (Ser40)
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Figure 9
Induction of secondary structure by the
formation of upstream rings may potentiate the
heterocyclization of all eight Cys/Ser sites in
McbA. (a) Dreiding model illustrating the
nucleation of a reverse turn (arrows) by the
4,2-linked oxazole–thiazole in McbA (rings are
labeled 1 and 2). The peptide termini are
N-acetylated and C-amidated in this model,
and double bonds are shaded. C, H, O, N and
S atoms are gray, green, red, blue and yellow,
respectively. (b) The amino-terminal propeptide
helix of McbA (gray cylinder) is recognized by
the McbD subunit of MccB17 synthetase
during the biosynthesis of MccB17. Transient
conformational perturbations similar to that
shown in (a) for rings 1 and 2 may accompany
the formation of each oxazole (red pentagon)
and thiazole (blue pentagon), and potentiate
the heterocyclization of downstream serine
residues (red rectangles) and cysteine residues
(blue rectangles) by increasing the frequency
of productive collisions between these
residues and the enzyme active site (McbB/C).
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presumably alters the conformational propensity of this
sequence in MMP2, reducing the frequency of produc-
tive encounters between Cys48 and the enzyme active
site. The cyclization of Cys51 further downstream is less
affected by such perturbations, because a change in back-
bone conformation induced by the cyclization of Cys41
alone (ring 2) is sufficient for the efficient modification of
this site in chimera MMP3. Significantly, the Asn53→Gly
substitution in this substrate failed to induce the cycliza-
tion of Ser52 (one of two unmodified serines in MccB17).
Hence, removal of a flanking polar residue known to
disrupt bisheterocyclization in McbA1–46 analogs [10] does
not rescue oxazole formation, indicating that even a slight
decrease in conformational rigidity due to the absence of
rings 1 and 3 may effectively suppress the modification of
this residue in MMP3, especially because the synthetase
processes serines significantly slower than cysteines [15].
Such an effect is heightened for the processing of
bisheterocyclic sites further downstream in chimeras
MMP4 (Gly54–Cys55–Ser56) and MMP5 (Gly54–
Cys55–Cys56), which incorporate knockouts at multiple
upstream sites (rings 1, 3 and 4). The 4,2-linked bithia-
zole forms in MMP5 to a small extent, although the
native 4,2-thiazole–oxazole moiety in MMP4 does not,
again reflecting the general inability to generate down-
stream oxazoles due to intrinsic chemoselectivity barriers
for serine cyclization [15,20].
Muir et al. [13] have noted that EPL allows nonstandard
amino acids to be incorporated into proteins. We have now
demonstrated that homocysteine replaces the amino-termi-
nal cysteine in peptides P6 and P7 for the EPL assembly
of chimeras MMP6 and MMP7. As with cysteine, capture
of the MM–Cys41-DTT α-thioester by homocysteine is
followed by rearrangement of the thioester linkage at the
splice junction to afford a native-like amide connectivity in
these chimeras. The formation of a six-membered ring is
predicted to be slower than that of a five-membered ring,
however, which might be one of the reasons why the syn-
thetase is unable to generate a six-ring dihydro or het-
eroaromatic ring from the Gly40–HCys41 sequence in
these chimeras. Because the synthetase does not stall at
this unnatural residue, the ‘silent’ Gly40–HCys41 splice
junction allowed thiazole 2 to be deleted for the first time
in the chimeric substrates. A progressive decrease in
cyclization efficiency of Cys48 upon deletion of ring 1
(MMP2) followed by rings 1 and 2 (MMP7) implicated
both heterocycles in facilitating the processing of this
residue, and reinforced the importance of upstream hetero-
cyclization for the efficient processing of McbA.
This study demonstrates the potentiation of heterocycliza-
tion by upstream rings in a family of McbA sequences
assembled by EPL. It is proposed that MccB17 synthetase
achieves the directional processing of multiple sites without
tight binding of intermediates by exploiting conformational
changes that increase the frequency of productive collisions
for subsequent heterocyclizations. Such ‘conformational fil-
tering’ may explain the synergism that controls the hetero-
cyclization process. The EPL methodology lays a
foundation for determining the optimal number and place-
ment of heterocyclization sites in McbA chimeras, and can
be used with peptidomimetics in thiol peptide libraries to
permit selection strategies for heterocyclic peptide antibi-
otics with increased protease resistance and potency.
Significance
The Escherichia coli peptide antibiotic microcin B17
(MccB17) contains thiazole and oxazole heterocycles,
derived from the post-translational cyclodehydration and
dehydrogenation of cysteine and serine residues between
positions 40 and 65 of the 69-residue McbA precursor.
These rings are presumably the active moieties that target
DNA gyrase in sensitive bacteria. Inhibition of the gyrase
catalytic cycle leads to double-strand DNA breaks, remi-
niscent of the mode of action of quinolone antibacterial
drugs. To probe the structure–activity requirements for
heterocycle content, placement and identity in MccB17,
and to determine which features are necessary and suffi-
cient for antibiotic activity, we have adopted a combina-
tion of molecular biology and protein chemistry
approaches. The amino-terminal 26 residues of McbA
provide high-affinity recognition for the post-translational
ring-forming McbB,C,D enzymes, and are essential to
any substrate. Hence, the first 40 residues were supplied
as an maltose binding protein (MBP)–McbA1–40(S40G)
fusion protein. The downstream sequence containing het-
erocyclizable serines and cysteines was delivered as a
series of synthetic peptides of varying length and composi-
tion. These peptides contained an amino-terminal cys-
teine or homocysteine residue to enable intein-mediated
expressed protein ligation for the assembly of MBP-
tagged McbA analogs (46–61 residues) that were purified
and used as substrates for heterocyclization by the
McbB,C,D complex. Structure–function studies of these
chimeras reveal considerable synergism in the progres-
sive enzymatic cyclization of particular cysteines and
serines in MccB17, and should be amenable to analysis of
the determinants of antibiotic activity in this class of hete-
rocyclic peptide antibiotics.
Materials and methods
Plasmids, peptides and antibodies
The MBP–McbA1–46(GGC) substrate was purified from plasmid
pMSS37 [15]. Plasmid pLARA15b, a pET15b derivative that encodes
His6-tagged McbA, has been reported previously [8]. Plasmid pTYB1
used for construction of the McbA–intein chimera was obtained from
New England Biolabs (Beverly, MA), as part of the ImpactTM T7 protein
purification system. Peptides P1–P7 were synthesized using solid-
phase Fmoc chemistry on an automated peptide synthesizer [21], puri-
fied using reversed phase C18 HPLC, and characterized by MALDI–
TOF MS. PAL-PEG-PSTM resin (PerSeptive Biosystems, MA) was used
to obtain carboxy-terminal primary amides. Heterocyclization of these
target peptide sequences upon incubation of the corresponding EPL
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chimeras with affinity-purified MccB17 synthetase was monitored by
western immunoblot assays using rabbit anti-MccB17 antibodies [16]
as previously described [10]. Rabbit anti-intein and anti-MBP antibod-
ies were purchased from New England Biolabs.
Construction of plasmids pMMIC and pET15b-McbA1–61
Plasmid pMMIC encoding the MBP–McbA1–40(S40G)–intein–CBD
protein was constructed by polymerase chain reaction (PCR) amplifica-
tion of the MBP–McbA1–40(S40G) gene as an NdeI–KpnI fragment from
plasmid pMSS37. Following digestion with NdeI and KpnI, the PCR
product was inserted into plasmid pTYB1 restricted with the same
enzymes, which placed the MBP–McbA1–40(S40G) coding sequence
upstream of, and in frame with, the gene encoding the intein–CBD
fusion. The resulting plasmid (pMMIC) was transformed into E. coli
strain DH5α. Plasmid pET15b-McbA1–61, which encodes the His6–
McbA1–61 substrate, was constructed by PCR amplification of the
McbA1–61 gene as an SphI–BamHI fragment from plasmid pLARA15b.
Two sequential stop codons were introduced in mcbA after the codon
for Gly61. Following digestion with SphI and BamHI, the PCR product
was ligated with the 5340 bp fragment obtained from plasmid pET15b-
McbA treated with the same restriction enzymes, and the resulting
plasmid (pET15b-McbA1–61) was transformed into E. coli strain
BL21(DE3) for protein expression. His6–McbA1–61 was expressed
using protocols reported for other His6-tagged proteins [18], and puri-
fied by immobilized metal-affinity chromatography using Ni-NTA resin
(Qiagen, CA) as per the manufacturer’s directions.
Overexpression and immobilization of MMIC protein
E. coli strain BL21(DE3) was used as the expression host for recombi-
nant MMIC (MBP–McbA1–40(GGC)–intein–CBD) protein. An overnight
culture in 10 ml of LB ampicillin (150 µg/ml) was grown at 37°C and
used to inoculate 1 l of LB ampicillin. Cultures were grown at 37°C and
induced with 1 mM IPTG at an OD600 of 0.5–0.7. After 3 h of induction,
the cells were harvested and resuspended in 20 ml of buffer A (20 mM
Na-Hepes pH 8.0, 500 mM NaCl, 1 mM EDTA) containing protease
inhibitors (chymostatin, leupeptin, aprotonin and Pefabloc (Boehringer
Mannheim)). The cells were disrupted twice in a French pressure cell
(18,000 psi) and cellular debris was removed by centrifugation
(18,000 g, 35 min). The supernatant was applied to (and recycled
through) a chitin column (2 ml bed volume) at a flow rate of 0.5 ml/min.
The column was washed with 20 column volumes of buffer B (buffer
A + 0.1% Triton X-100), and the purified MMIC protein was retained on
the chitin beads for subsequent ligation with target peptides P1–P7.
Expressed protein ligation
The ligation reactions were performed using the protocols of Muir et al.
[13] with some modifications. The chitin column containing immobilized
MMIC protein was washed with two column volumes of buffer C (buffer
A + 30 mM DTT). The column was then loaded with one column volume
of a 2 mM solution of target peptide (P1–P7) in buffer C. The column
was subsequently disassembled and the chitin beads were transferred
to eppendorf tubes, which were shaken at room temperature for
48–72 h. The chitin column was subsequently repacked, and 6 × 1.5 ml
fractions were eluted with buffer A. The fractions containing ligated MMP
(MBP–McbA1–40(S40G)–peptide) chimera were identified using
SDS–PAGE, pooled, exchanged into buffer D (50 mM Tris–HCl pH 7.5),
and concentrated using a Centricon 30 concentration unit (Millipore,
MA). Protein concentration was determined by UV spectroscopy, and
extinction coefficients (ε280 = 66,350 M–1 cm–1 for all ligated proteins)
were determined by a modification of the Edelhoch method [22,23].
Mass spectrometry and iodoacetamide labeling
Assay mixtures consisted of 50 µM MBP–McbA1–40(S40G)–peptide
(MMP) ligated substrate, assay buffer (50 mM Tris pH 7.5, 100 mM
NaCl, 20 mM MgCl2, 10 mM DTT, 2 mM ATP), and affinity-purified
CBP-tagged MccB17 synthetase (0.17 mg/ml, 50 µl) in a total
volume of 100 µl. Reactions were incubated at 37°C for 24–40 h.
The MBP affinity tag was removed by digestion with thrombin
(0.246 units; 2 h at 25°C), which leaves a Gly–Ser dipeptide
appended to the amino terminus of the downstream McbA fragment.
The cleaved McbA1–40 peptide fragments were purified on an analyti-
cal C18 reversed-phase HPLC column using a Beckman System
Gold HPLC (A = water + 0.1% TFA; B = acetonitrile + 0.1% TFA;
30–42% B linear gradient over 12 min, tR = 6–8 min). The hetero-
cyclic peptides were collected, lyophilized and analyzed by
MALDI–TOF MS as described previously [11]. The heterocyclization
products obtained with target peptides P2–P4 were further investi-
gated by iodoacetamide labeling to detect the presence of uncy-
clized cysteines. The HPLC-purified heterocyclic McbA1–40 peptide
fragments were dissolved in 100 µl of labeling buffer (50 mM
Tris–HCl, pH 8.5, 1 mM EDTA, 5 mM iodoacetamide) and incubated
at 25°C for 4 h. The labeling reaction was quenched with 400 µl
wash buffer (1% acetic acid, 1% methanol in water), and samples
were desalted by passage through a reversed-phase peptide trap
(0.1 mm i.d.; Michrom Bioresources, CA) prior to analysis by
MALDI–TOF MS. McbA fragments obtained from thrombin-digested
chimeras MMP6 and MMP7 were HPLC-purified, treated with
iodoacetamide, and analyzed by MALDI–TOF MS to determine free
thiol content using the same protocols.
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